Search | Page 8 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117

    ... (MDS). Whether azacitidine-based combinations with lenalidomide or vorinostat produce superior overall response rates (ORRs) ... on days 1 to 7 of a 28-day cycle); azacitidine plus lenalidomide (10 mg/day on days 1 to 21); or azacitidine plus vorinostat (300 ...

    Research Article last updated 05/22/2017 - 10:52am.

  2. Alaskan Goes Home for Treatment and a Fresh Start

    ... was also when my treatments began. I was placed on lenalidomide (Revlimid®) injections for 12 weeks at which point it was ...

    Patient Chronicle last updated 04/26/2018 - 10:17am.

  3. Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy.

    ... While lenalidomide (LEN) is the standard of care for the lower-risk ... 5q deletion and to analyze their outcome after failure of lenalidomide. The median survival following LEN failure was 23 months. We ...

    Research Article last updated 07/11/2017 - 10:11am.

  4. Our History

    ... FDA approves Revlimid® ( lenalidomide ) as a therapy for the treatment of myelodysplastic ... FDA approves Revlimid® (lenalidomide) as a therapy for the treatment of myelodysplastic syndromes ...

    Page last updated 09/20/2018 - 11:26am.

  5. Cellular immune profiling after sequential clofarabine and lenalidomide for high risk myelodysplastic syndromes and acute myeloid leukemia

    ... of four cases receiving sequential clofarabine and lenalidomide for high risk MDS and AML in a phase I study. Our results ...

    Research Article last updated 05/22/2017 - 11:42am.

  6. Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications

    ... to AML among patients with lower-risk MDS (LR-MDS). Lenalidomide is the drug with the most impressive clinical activity in the ... independence and cytogenetic responses. Furthermore, lenalidomide delays progression to AML and prolongs survival among responders. ...

    Research Article last updated 02/21/2017 - 9:34am.

  7. Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents

    ... double-blind study assessed the efficacy and safety of lenalidomide in RBC transfusion-dependent patients with International ... 239 patients were randomly assigned (2:1) to treatment with lenalidomide (n = 160) or placebo (n = 79) once per day (on 28-day cycles). The ...

    Research Article last updated 07/18/2016 - 10:30am.

  8. Efficacy and Safety of Lenalidomide for Treatment of Low-/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-Analysis

    ... BACKGROUND: Lenalidomide could effectively induce red blood cell (RBC) ... syndrome (MDS) with or without 5q deletion. However whether lenalidomide ultimately improves the overall survival (OS) of lower-risk MDS ...

    Research Article last updated 11/28/2016 - 9:36am.

  9. Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy

    ... in lower-risk myelodysplastic syndromes (MDS). Lenalidomide (LEN) can correct anemia in 25% of MDS patients without ...

    Research Article last updated 02/21/2017 - 9:43am.

  10. A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher-risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasia

    ... with trilineage dysplasia (AML-TD). High dose (HD) lenalidomide (50 mg) has activity as frontline therapy in elderly AML but ... included patients with RR HR-MDS or AML-TD at 2 doses of lenalidomide (15 or 50 mg) on days 1-28 of 42-day cycles. The primary endpoint ...

    Research Article last updated 11/02/2016 - 9:17am.